Hyeong‐Seok Lim

2.5k total citations
91 papers, 1.9k citations indexed

About

Hyeong‐Seok Lim is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Hyeong‐Seok Lim has authored 91 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 20 papers in Molecular Biology and 18 papers in Pharmacology. Recurrent topics in Hyeong‐Seok Lim's work include Pharmacogenetics and Drug Metabolism (15 papers), Cancer therapeutics and mechanisms (10 papers) and Drug Transport and Resistance Mechanisms (9 papers). Hyeong‐Seok Lim is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Cancer therapeutics and mechanisms (10 papers) and Drug Transport and Resistance Mechanisms (9 papers). Hyeong‐Seok Lim collaborates with scholars based in South Korea, United States and Ethiopia. Hyeong‐Seok Lim's co-authors include In‐Jin Jang, Kyun‐Seop Bae, Ji‐Youn Han, Yong Hoon Park, Eun‐Soon Shin, Jin Soo Lee, Keun Seok Lee, Jungsil Ro, Yeon-Kyeong Yoo and Jong-Eun Lee and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Hyeong‐Seok Lim

86 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hyeong‐Seok Lim South Korea 21 795 622 375 280 252 91 1.9k
Roberto Mazzanti Italy 27 820 1.0× 820 1.3× 144 0.4× 457 1.6× 336 1.3× 77 2.8k
Julia M. Barbarino United States 13 449 0.6× 418 0.7× 567 1.5× 139 0.5× 107 0.4× 14 1.6k
Joseph A. Ware United States 25 999 1.3× 814 1.3× 385 1.0× 152 0.5× 327 1.3× 70 2.2k
Mark J. Dresser United States 24 1.3k 1.6× 697 1.1× 274 0.7× 153 0.5× 258 1.0× 49 2.5k
Janelle M. Hoskins United States 23 1.0k 1.3× 805 1.3× 479 1.3× 160 0.6× 201 0.8× 72 2.3k
Floris A. de Jong Netherlands 23 1.2k 1.5× 648 1.0× 178 0.5× 198 0.7× 331 1.3× 54 1.9k
Kohshi Nishiguchi Japan 19 449 0.6× 318 0.5× 221 0.6× 215 0.8× 136 0.5× 81 1.2k
Edmund J.D. Lee Singapore 26 1.0k 1.3× 577 0.9× 583 1.6× 162 0.6× 98 0.4× 45 2.0k
Nobuo Aoyama Japan 28 1.2k 1.6× 566 0.9× 398 1.1× 1.2k 4.4× 425 1.7× 98 3.0k
Barry R. Goldspiel United States 31 1.4k 1.8× 1.2k 2.0× 233 0.6× 193 0.7× 335 1.3× 66 3.1k

Countries citing papers authored by Hyeong‐Seok Lim

Since Specialization
Citations

This map shows the geographic impact of Hyeong‐Seok Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyeong‐Seok Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyeong‐Seok Lim more than expected).

Fields of papers citing papers by Hyeong‐Seok Lim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyeong‐Seok Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyeong‐Seok Lim. The network helps show where Hyeong‐Seok Lim may publish in the future.

Co-authorship network of co-authors of Hyeong‐Seok Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Hyeong‐Seok Lim. A scholar is included among the top collaborators of Hyeong‐Seok Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hyeong‐Seok Lim. Hyeong‐Seok Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lim, Hyeong‐Seok, et al.. (2025). Evaluation of drug-drug interaction potentials between JP-1366 and celecoxib using physiologically based pharmacokinetic modeling. Translational and Clinical Pharmacology. 33(2). 90–90.
2.
Kim, Hyungsub, et al.. (2022). Pharmacokinetic Drug Interaction Between Amlodipine and Tadalafil: An Open-Label, Randomized, Multiple-Dose Crossover Study in Healthy Male Volunteers. SHILAP Revista de lepidopterología. 1 indexed citations
3.
Kang, Dong‐Wha, et al.. (2021). Modeling and simulation to predict the degree of disability over time in acute ischemic stroke patients. Clinical and Translational Science. 14(5). 1988–1996.
4.
5.
Han, Sungpil, Hee Youn Choi, Yo Han Kim, et al.. (2021). Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Tegoprazan. Clinical Therapeutics. 43(8). 1371–1380. 20 indexed citations
6.
Lim, Hyeong‐Seok, et al.. (2019). Performance of a mixture model by the degree of a missing categorical covariate when estimating clearance in NONMEM. Translational and Clinical Pharmacology. 27(4). 141–141. 2 indexed citations
7.
Song, In‐Kyung, SoJeong Yi, Hyeong‐Seok Lim, et al.. (2019). A Population Pharmacokinetic Model of Intravenous Dexmedetomidine for Mechanically Ventilated Children after Neurosurgery. Journal of Clinical Medicine. 8(10). 1563–1563. 9 indexed citations
8.
Han, Sungpil, et al.. (2019). Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin. Pharmaceutical Research. 36(10). 146–146. 3 indexed citations
9.
Hong, Junshik, Soo‐Mee Bang, Yeung‐Chul Mun, et al.. (2018). Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP). Journal of Korean Medical Science. 33(19). e142–e142. 8 indexed citations
10.
Cho, Yong‐Soon, et al.. (2018). Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LCB01-0371 in Healthy Male Volunteers. Clinical Therapeutics. 40(12). 2050–2064. 12 indexed citations
11.
Kim, Hyungsub, Hee Youn Choi, Yohan Kim, et al.. (2018). Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. Drug Design Development and Therapy. Volume 12. 815–821. 11 indexed citations
12.
Cho, Yong‐Soon, Hyeong‐Seok Lim, Sungpil Han, et al.. (2018). Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371. Clinical Therapeutics. 41(1). 92–106. 10 indexed citations
13.
14.
Bae, Kyun‐Seop, et al.. (2015). Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers. Drug Design Development and Therapy. 9. 1209–1209. 7 indexed citations
15.
Kim, Bo‐Hyung, Hyeong‐Seok Lim, Jae‐Yong Chung, et al.. (2008). Safety, tolerability and pharmacokinetics of udenafil, a novel PDE‐5 inhibitor, in healthy young Korean subjects. British Journal of Clinical Pharmacology. 65(6). 848–854. 58 indexed citations
16.
17.
Han, Ji‐Youn, Hyeong‐Seok Lim, Eun‐Soon Shin, et al.. (2007). Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer. Cancer. 110(1). 138–147. 157 indexed citations
18.
Han, Ji‐Youn, Hyeong‐Seok Lim, Dae Ho Lee, et al.. (2006). Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 106(4). 873–880. 21 indexed citations
19.
Jang, In‐Jin, et al.. (2003). Variability in Drug Interaction According to Genetic Polymorphisms in Drug Metabolizing Enzymes. 23(4). 131–134. 1 indexed citations
20.
Yu, Kyung‐Sang, Kyun‐Seop Bae, Ji‐Hong Shon, et al.. (2003). Pharmacokinetic and Pharmacodynamic Evaluation of a Novel Proton Pump Inhibitor, YH1885, in Healthy Volunteers. The Journal of Clinical Pharmacology. 44(1). 73–82. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberto Mazzanti Breakdown of academic impact, for papers by Julia M. Barbarino Breakdown of academic impact, for papers by Joseph A. Ware Breakdown of academic impact, for papers by Mark J. Dresser Breakdown of academic impact, for papers by Janelle M. Hoskins Breakdown of academic impact, for papers by Floris A. de Jong Breakdown of academic impact, for papers by Kohshi Nishiguchi Breakdown of academic impact, for papers by Edmund J.D. Lee Breakdown of academic impact, for papers by Nobuo Aoyama Breakdown of academic impact, for papers by Barry R. Goldspiel
Rankless by CCL
2026